Literature DB >> 19710096

Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity.

Ebbe Billmann Thorgersen1, Judith K Ludviksen, John D Lambris, Georgia Sfyroera, Erik Waage Nielsen, Tom Eirik Mollnes.   

Abstract

C1-Inhibitor (C1-INH) is an important biological inhibitor, regulating several protein cascade systems. Recent research has shown that the molecule exhibits properties not dependent on its protease inhibition activity. Serum and whole blood from pigs and humans were pre-incubated with C1-INH, iC1-INH or the complement inhibitors SPICE or compstatin. Whole, live Escherichia coli were then added for further incubation. Complement activation, a range of cytokines, chemokines and growth factors, as well as the leukocyte activation markers wCD11R3 (pig) and CD11b (human) were measured. Both C1-INH and iC1-INH dose-dependently and significantly (P<0.05) reduced a range of E. coli-induced pro-inflammatory cytokines and chemokines in porcine and human whole blood, as well as growth factors in human whole blood. Differences between the two forms of C1-INH and between the two species were modest. Most of these anti-inflammatory effects could not be explained by complement inhibition, as specific complement inhibitors had minor effect on several of the mediators. C1-Inhibitor had no inhibitory effect on E. coli-induced complement activation, while iC1-INH enhanced complement activation. The presented data indicate that C1-INH has broad anti-inflammatory effects in E. coli-induced inflammation in pig and human whole blood. These effects are largely independent of the protease inhibition activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710096      PMCID: PMC2891294          DOI: 10.1177/1753425909340420

Source DB:  PubMed          Journal:  Innate Immun        ISSN: 1753-4259            Impact factor:   2.680


  38 in total

1.  C1-inhibitor reduces the ischaemia-reperfusion injury of skeletal muscles in mice after aortic cross-clamping.

Authors:  E W Nielsen; T E Mollnes; J M Harlan; R K Winn
Journal:  Scand J Immunol       Date:  2002-12       Impact factor: 3.487

2.  Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus.

Authors:  E S Kalter; W C van Dijk; A Timmerman; J Verhoef; B N Bouma
Journal:  J Infect Dis       Date:  1983-10       Impact factor: 5.226

3.  Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation.

Authors:  Tom Eirik Mollnes; Ole-Lars Brekke; Michael Fung; Hilde Fure; Dorte Christiansen; Grethe Bergseth; Vibeke Videm; Knut Tore Lappegård; Jörg Köhl; John D Lambris
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

4.  Demonstration of the interaction of native C1 with monomeric immunoglobulins and C1 inhibitor.

Authors:  R J Ziccardi
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

5.  The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q.

Authors:  Maria Grazia De Simoni; Emanuela Rossi; Claudio Storini; Simone Pizzimenti; Cinara Echart; Luigi Bergamaschini
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

6.  Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion.

Authors:  Shenghe Cai; Alvin E Davis
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

7.  Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism.

Authors:  R J Ziccardi
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

8.  C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide.

Authors:  Dongxu Liu; Shenghe Cai; Xiaogang Gu; Jennifer Scafidi; Xiao Wu; Alvin E Davis
Journal:  J Immunol       Date:  2003-09-01       Impact factor: 5.422

Review 9.  The dark side of C5a in sepsis.

Authors:  Peter A Ward
Journal:  Nat Rev Immunol       Date:  2004-02       Impact factor: 53.106

10.  N-linked glycosylation is required for c1 inhibitor-mediated protection from endotoxin shock in mice.

Authors:  Dongxu Liu; Xiaogang Gu; Jennifer Scafidi; Alvin E Davis
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

View more
  5 in total

1.  Interleukin-8 mediates neutrophil-endothelial interactions in pig-to-human xenogeneic models.

Authors:  Beth M French; Selin Sendil; Krishna Mohan Sepuru; Jolene Ranek; Lars Burdorf; Donald Harris; Emily Redding; Xiangfei Cheng; Christopher T Laird; Yuming Zhao; Benjamin Cerel; Krishna Rajarathnam; Richard N Pierson; Agnes M Azimzadeh
Journal:  Xenotransplantation       Date:  2018-02-09       Impact factor: 3.907

2.  C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood.

Authors:  A Landsem; E W Nielsen; H Fure; D Christiansen; J K Ludviksen; J D Lambris; B Østerud; T E Mollnes; O-L Brekke
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

3.  Progress and Trends in Complement Therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

4.  Two-dimensional difference gel electrophoresis (DIGE) analysis of sera from visceral leishmaniasis patients.

Authors:  Lokesh A Rukmangadachar; Jitender Kataria; Gururao Hariprasad; Jyotish C Samantaray; Alagiri Srinivasan
Journal:  Clin Proteomics       Date:  2011-05-31       Impact factor: 3.988

5.  Human plasma-derived C1 esterase inhibitor concentrate has limited effect on house dust mite-induced allergic lung inflammation in mice.

Authors:  Ingrid Stroo; Jack Yang; Adam A Anas; J Daan de Boer; Gerard van Mierlo; Dorina Roem; Diana Wouters; Ruchira Engel; Joris J T H Roelofs; Cornelis van 't Veer; Tom van der Poll; Sacha Zeerleder
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.